Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

Author： Hare Jennifer I.   Moase Elaine H.   Allen Theresa M.  

Publisher： Informa Healthcare

ISSN： 1061-186X

Source： Journal of Drug Targeting, Vol.21, Iss.1, 2013-01, pp. : 87-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 3, 2008-09 ,pp. : 225-233

Bentham Science Publishers

Access to resources Recommend Favorite

Nuclear Targeting and Retention of Anthracycline Antitumor Drugs in Sensitive and Resistant Tumor Cells

By  

Current Medicinal Chemistry, Vol. 8, Iss. 1, 2001-01 ,pp. : 15-29

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes

By Abu Lila Amr   Ishida Tatsuhiro   Kiwada Hiroshi  

Pharmaceutical Research, Vol. 27, Iss. 7, 2010-07 ,pp. : 1171-1183

Springer Publishing Company

Access to resources Recommend Favorite

Circulating Tumor Cells and Tumor Stem Cells Detection in the Peripheral Blood Mononuclear Cells of Breast Cancer

By  

Journal Of Clinical Laboratory Analysis (Electronic), Vol. 30, Iss. 5, 2016-09 ,pp. : 616-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Current and Future Treatment Strategies

By Engel Ryan H.   Kaklamani Virginia G.  

Drugs, Vol. 67, Iss. 9, 2007-01 ,pp. : 1329-1341

Adis International

Access to resources Recommend Favorite